A5175 -A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor- And Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations For Initial Treatment Of HIV-1 Infected Individuals From Resource-Limited Settings (PEARLS) Trial
A5199 -International Neurological Study- A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals from Diverse Areas of the World)
A5185 -Effect of Antiretroviral treatment of Genital Compartment virus in individuals initiating Potent Antiretroviral therapy from Resource limited settings.
A5207- Maintaining Options for Mothers Study (MOMS) – A Phase II Randomized Comparison of three Antiretroviral Strategies administered for 7 or 21 days to reduce the emergence of Nevirapine resistant HIV-1 following a single Intrapartum dose of Nevirapine
A5190- Assessment of Safety and Toxicity among Infants Born To HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World – A Limited Center Trial of the Adult AIDS Clinical Trials Group (AACTG) and the Pediatric AIDS Clinical Trials Group (PACTG), Conducted in Collaboration with the HIV Prevention Trials Network (HPTN)
A5221-STRIDE -A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 < 250 Cells/mm3
A5230- A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens
A5265/GIVEN, “A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings
A5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT), A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
